Pregnant women have consistently been underrepresented in clinical trials. With pregnancy studies posing significant risks to the mother and fetus, requiring extensive follow-up procedures, and potentially jeopardizing market approvals, many pharmaceutical companies avoid this demographic almost entirely. As a result, healthcare providers often struggle to access data regarding drug safety in pregnancy, preventing them from administering the best care possible. “Pregnant people make decisions in a vacuum of evidence. Very often, their healthcare providers don’t know the evidence, so the women actually make the decision and take the risk that everyone else is ignoring. I think that has to stop,” says podcast guest Dr. Anna David, obstetrician and director of the University College London Institute for Women's Health.
In this episode, host Deborah Borfitz speaks with David about the obstacles facing pregnant patients in today’s medical landscape and the past and present strides made to increase their representation in clinical research. David also talks about her work creating the first standardized vocabulary for drug safety and maternal-fetal adverse events, how COVID-19 changed the industry’s perspective regarding pregnancy studies, and the novel trials currently fostering change across the globe.
Links from this episode:
Clinical Research News
University College London
UCL EGA Institute for Women's Health
Innovative Medicines Initiative ConcePTION Project
Accelerating Innovation for Mothers
International Council for Harmonisation
Healthy Mum, Healthy Baby, Healthy Future
Paediatric Investigation Plan (PIP)
Maternal and Fetal Adverse Event Terminology
Pregnant women have consistently been underrepresented in clinical trials. With pregnancy studies posing significant risks to the mother and fetus, requiring extensive follow-up procedures, and potentially jeopardizing market approvals, many pharmaceutical companies avoid this demographic almost entirely. As a result, healthcare providers often struggle to access data regarding drug safety in pregnancy, preventing them from administering the best care possible. “Pregnant people make decisions in a vacuum of evidence. Very often, their healthcare providers don’t know the evidence, so the women actually make the decision and take the risk that everyone else is ignoring. I think that has to stop,” says podcast guest Dr. Anna David, obstetrician and director of the University College London Institute for Women's Health.
In this episode, host Deborah Borfitz speaks with David about the obstacles facing pregnant patients in today’s medical landscape and the past and present strides made to increase their representation in clinical research. David also talks about her work creating the first standardized vocabulary for drug safety and maternal-fetal adverse events, how COVID-19 changed the industry’s perspective regarding pregnancy studies, and the novel trials currently fostering change across the globe.
Links from this episode:
Clinical Research News
University College London
UCL EGA Institute for Women's Health
Innovative Medicines Initiative ConcePTION Project
Accelerating Innovation for Mothers
International Council for Harmonisation
Healthy Mum, Healthy Baby, Healthy Future
Paediatric Investigation Plan (PIP)
Maternal and Fetal Adverse Event Terminology